A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：IDRUGS ISSN： 1369-7056 出版频率： Monthly 出版社： THOMSON REUTERS (SCIENTIFIC) LTD, 77 HATTON GARDEN, LONDON, ENGLAND, EC1N 8JS   出版社网址： http://www.biomedcentral.com/ 期刊网址： http://www.biomedcentral.com/libraries/subsproducts/co 影响因子： 2.782 主题范畴： PHARMACOLOGY & PHARMACY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal IDrugs - Aims and Scope The IDdb3 is the world's leading competitor intelligence (CI) service on drug R&D. Updated nightly, the IDdb3 covers all aspects of drug development world wide. IDrugs draws on the IDdb3 by focusing on the most relevant meetings whilst also highlighting important feature articles and drug evaluations. Now in its ninth year of publication, IDrugs has firmly established itself as an essential monthly update for pharmaceutical R&D workers from across the world. Instructions to Authors Articles published in Current Opinion in Drug Discovery & Development, Current Opinion in Molecular Therapeutics, Current Opinion in Investigational Drugs and IDrugs are by invitation via the journal Editors based on the recommendations of the Editorial Board members of these journals. We also welcome proposals, and authors wishing to submit an article to a relevant journal should contact the Editor with an outline/abstract, which will be sent to a member of the Editorial Board for approval. The Current Opinion journals are review-based (we do not publish primary papers) and all articles are peer reviewed. IDrugs contains feature articles which highlight and debate topics of current interest in the field. Preparation of manuscripts The Editors will provide details of guidelines for authors and a deadline for submission on approval of the commission. Proofs Page proofs will be sent to the corresponding author for final corrections and approval before publication. Offprints Ten offprints will be provided per author free of charge. Additional copies can be purchased at prices shown on the reprint order form, which is sent with the page proofs. Editorial correspondence Address all correspondence to: Thomson Scientific Commissioning Thomson Scientific 77 Hatton Garden London EC1N 8JS UK TS-EMEA-Commissioning@thomson.com Points to consider Is the subject current and of sufficient interest to other people? The article should be of interest to a range of researchers, and therefore address a subject of common concern. Of course, you may wish to discuss a new (or neglected) subject in light of your belief that it will become of greater significance, in which case please address this in your piece. It is important that your article looks 'outwards' rather than 'inwards', addressing researchers in many fields; this is particularly important if your aim in writing the feature is to persuade readers to your way of thinking. Consider whether you are writing too much with specialists in mind? It is easy to fall into jargon, yet one of the aims of the features is to enlighten qualified, but non-specialist, researchers with developments they may be unaware of or arguments that they may not have heard before. Has the subject been sufficiently covered in other recent publications? This follows on from the point above; although a subject may be of current interest or controversy, it may also be that there is little remaining to be said. If writing about such a subject, please consider recent articles when writing your piece and try to avoid repetition, unless addressing specific points raised by the said articles. If addressing a perceived problem, do I have any answers of my own? It is easy to be critical, less easy to provide alternatives, and we encourage authors to do so. Editorial Board IDrugs - Editorial Board Overseeing the editorial content and development of the journal is an Editorial Board, composed of many of the world's leading experts within the area of drug discovery and development. Sudhir Agrawal - Hybridon, USA Gary P Anderson - University of Melbourne, Australia Koshi Arai - Taisho, Japan John F Barrett - Merck & Co Inc, USA Robert Beamer - University of South Carolina, USA Nigel Beeley - Arena Pharmaceuticals, USA Stanley C Bell - Allelix Neuroscience, Canada Francois D Bellamy - Laboratoires Fournier, France Scott Biller - Novartis Institute for Biomedical Research, USA Frederik Bjorkling - Leo Pharmaceuticals, Denmark David P Bloxham - Evolutec, UK Mike Briley - NeuroBiz, France James A Bristol - Pfizer Inc, USA Clint Brooks - Abbott Laboratories, USA Leslie J Browne - Iconix Pharmaceuticals Inc, USA Andre Bryskier - Aventis, France Simon Campbell - Ex-Pfizer, UK Roberto Ceserani - Roche, Italy Daniel TW Chu - Chiron Corp, USA John C Clapham - Astra Zeneca, UK Tom Colatsky - Paradigm Genetics, USA Stanley T Crooke - ISIS Pharmaceuticals, USA Roger Crossley - BioFocus, UK Erik de Clercq - Rega Institute for Medical Research, Belgium Robert E Davis - ACADIA Pharmaceuticals, USA Scott Dax - RW Johnson Pharmaceutical Research Institute, USA Annette Doherty - Pfizer, France J. Drews - Ex-Hofmann-La Roche, USA Gerard Emilien - Catholic University of Louvain, France Jay Gibbs - Merck Research Laboratories, USA Steven Gillis - Corixa Corporation, USA William E Heydorn - Forest Laboratories, USA Ray Hill - Merck & Co, UK Richard Houghten - Torrey Pines Institute for Molecular Studies, USA Victor J Hruby - University of Arizona, USA Ian Hunneyball - EVOTEC, UK Kim D Janda - The Scripps Research Institute, USA Graham Johnson - Rib-X Pharmaceuticals, USA Taff (David H) Jones - ID Biomedical Corp, Canada Ulrich Jordis - Institute of Applied Synthetic Chemistry, Austria Barry L Karger - Northeastern University, USA Mads Krogsgaard Thomsen - Novo Nordisk, Denmark Donald J Kyle - Purdue Pharma, USA Kit S Lam - US Davis Cancer Center, USA Gerard Le Fur - Sanofi Synthelabo, France Alex Levitzki - Hebrew University, Israel Ronald Magolda - Boehringer Ingelheim, USA John P Mallamo - Cephalon, USA Paolo Mascagni - Italfarmaco, Italy John M McCall - Pharmacia, USA Lester A Mitscher - University of Kansas, USA Brett P Monia - ISIS Pharmaceuticals, USA Walter H Moos - MitoKor, USA F Richard Nichol - CoCensys, USA Kyriacos C Nicolaou - The Scripps Research Institute, USA Peter E Nielsen - The Panum Institute, Denmark A Nistri - International School for Advanced Studies, Italy Stella O'Donnell - University of Queensland, Australia Jill Ann Panetta - Lilly Research Laboratories, USA Norton P Peet - Aurigene Discovery Technologies, USA George Perry - University of Texas at San Antonio, USA Petpiboon Peppi Prasit - Merck Research Laboratories, Canada Edward Petrillo - Bristol-Myers Squibb, USA George Poste - Health Technology Networks, USA PRK Reddy - University of Hyderabad, India Daniel H Rich - University of Wisconsin-Madison, USA Erich Schlick - Knoll, Germany Naj Sharif - Alcon Laboratories, USA Robert D Sindelar - University of British Columbia, Canada  Keith Suckling - GlaxoSmithKline, UK Mark J Suto - Neurion Pharmaceuticals, USA Grace Tang - The University of Hong Kong, Hong Kong Bernard Testa - Lausanne University, Switzerland David J Triggle - State University of New York at Buffalo, USA Marc Vasseur - GENSET, France Michael D Varney - Pfizer, USA Ruth R Wexler - Bristol-Myers Squibb, USA George Whitesides - Harvard University, USA Wendell Wierenga - Syrrx Inc, USA Michael Williams - Northwestern University, USA Zbigniew Witczak - Wilkes University, USA Paul L Wood - OxoN Medica, USA